Regeneron Pharmaceuticals (NQ:REGN)

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

November 13, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

November 09, 2023

Via InvestorPlace

Topics Economy

Where Regeneron Pharmaceuticals Stands With Analysts

November 09, 2023

Via Benzinga

2 Soaring Stocks to Buy and Hold

November 09, 2023

Both of these companies crushed earnings season.

The launch of high-dose Eylea is off to a strong start in the U.S.

Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers

November 02, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

Regeneron Pharmaceuticals Unusual Options Activity

November 01, 2023

Via Benzinga

$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

October 31, 2023

Via Benzinga

3 Biotech Stocks That Are Betting on the Future of Gene Editing

November 09, 2023

Via InvestorPlace

Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi

November 06, 2023

The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.

Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during...

Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?

November 06, 2023

Via Benzinga

Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review

November 03, 2023

Thursday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported better-than-

Via Benzinga

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week

October 30, 2023

S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.

Via Benzinga

Topics Economy Stocks

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

November 03, 2023

Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug

November 02, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate

Via Benzinga

US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple

November 02, 2023

After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick.

Via Benzinga

Topics Economy

1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years

November 02, 2023

Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.

Regeneron Reports Third Quarter 2023 Financial and Operating Results

November 02, 2023

EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema

November 01, 2023

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient...

Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic.

Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech

November 01, 2023

Via Talk Markets

Earnings Scheduled For November 2, 2023

November 02, 2023

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.

Via Benzinga

MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer

October 30, 2023

New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.

Via Benzinga

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More

October 28, 2023

The U.S.

Via Benzinga

SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff

October 27, 2023

The happy talk in Sanofi's press release didn't help with analysts, who have been disappointed in the company and SNY stock all year.

Via InvestorPlace

Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

October 26, 2023

The companies on our list combine high sustainability scores and top stock ratings.

IBD's 100 Best ESG Companies For 2023

October 27, 2023

Regeneron Announces Investor Conference Presentations

October 25, 2023

Neither company has discussed it, at least not yet.

Stock-Split Watch: Could These 2 Growth Stocks Be Next?

October 25, 2023